Pfizer-BioNTech Vaccine Reduces the Transmission Rate of Coronavirus

Aug, 2021 - By SMI

Pfizer-BioNTech Vaccine Reduces the Transmission Rate of Coronavirus

A study conducted by a team of researchers revealed that Pfizer-BioNTech vaccine reduce the transmission rate of Coronavirus and provide protection against susceptibility to infection.

The ongoing COVID-19 pandemic has caused disruptions to public health and economic wellbeing worldwide. Scientists and researchers are trying to develop novel therapeutics since the inception of COVID-19. Interestingly, they succeeded in their trial and have developed COVID-19 vaccines at a record speed, and many of these vaccines received approval from the various global regulatory bodies. For instance, in December 2020, the U.S. Food and Drug Administration (FDA) and World Health Organization (WHO) authorized the emergency use of Pfizer-BioNTech vaccine or BNT162b2 in 16 years of age or older individuals in order to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2. Moreover, various countries have started vaccination programs to combat the virus, as researchers believe that the fast global vaccination is the significant step in preventing the virus. The researchers believed that if vaccination can stop transmission of the virus from infected to healthy individuals, then also the ongoing pandemic can be controlled. There are limited studies available to prove the effects of vaccination on the transmission of SARS-CoV-2. However, the researchers have concluded in some of these limited studies that the vaccines have the potential to decrease transmission in healthcare individuals and others. Moreover, some of the previous studies have also revealed that vaccines reduce the viral load in the upper respiratory tract of the COVID-19 patients, thereby, reducing the probable chances of viral spread. In the recent study, the researchers have considered 2,305,704 individuals from 1,275,015 households. The researchers found 1,276,311 individuals received two doses of BNT162b2 vaccines. The researchers obtained the data for the period between June 15, 2020, and March 24, 2021 from Maccabi Healthcare Services (MHS), an Israel-based healthcare organization. The researchers observed that 4,141 individuals contracted the virus even after receiving both vaccine doses. They observed those COVID-19 patients who had two or more other household members to determine the rate of transmission.

The researchers revealed that BNT162b2 vaccine is effective in providing significant protection against the vulnerability to infection and also reduce the transmission rate of infection among household members.

Stratagem Market Insights

533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

Delivery Center

403, 4th Floor, Bremen Business Center
Aundh, Pune, Maharashtra 411007

Contact Us

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.